Coloplast (CPSE:COLO B) - Hisse Senedi Fiyatı, Haberler ve Analizler

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

COLO B Stoklara Genel Bakış

Coloplast A/S, Danimarka, Amerika Birleşik Devletleri, Birleşik Krallık, Fransa'da ve uluslararası alanda samimi sağlık ürünleri ve hizmetlerinin geliştirilmesi ve satışı ile ilgilenmektedir.

Şirket hakkında

COLO B temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	2/6
Finansal Sağlık	1/6
Temettüler	3/6

Ödüller

Adil değer tahminimizden 39.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 13.09% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 4.8% oranında arttı

Risk Analizi

Borç işletme nakit akışı tarafından iyi karşılanmıyor

2.4% temettüsü kazançlar veya serbest nakit akışları tarafından iyi karşılanmıyor

Coloplast A/S Rakipler

Demant

CPSE:DEMANT

DKK 58.6b

Ambu

CPSE:AMBU B

DKK 34.5b

Cooper Companies

NasdaqGS:COO

US$21.3b

Embla Medical hf

CPSE:EMBLA

DKK 14.4b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Coloplast
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	DKK 896.40
52 Haftanın En Yüksek Seviyesi	DKK 977.60
52 Haftanın En Düşük Seviyesi	DKK 689.20
Beta	0.33
11 Aylık Değişim	-1.62%
3 Aylık Değişim	4.52%
1 Yıllık Değişim	22.90%
33 Yıllık Değişim	-15.19%
5 Yıllık Değişim	12.50%
Halka arzdan bu yana değişim	6,915.31%

Son Haberler & Güncellemeler

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23

Recent updates

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Oct 18

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Aug 23

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Aug 22

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

Jul 17

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jun 29

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

May 21

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

May 10

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

May 09

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 04

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Nov 16

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Sep 30

Is Coloplast (CPH:COLO B) A Risky Investment?

Jun 28

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Jun 10

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Mar 22

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

Mar 01

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Dec 14

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Nov 26

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Nov 25

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Nov 11

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Oct 25

Estimating The Fair Value Of Coloplast A/S (CPH:COLO B)

Aug 26

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Jul 27

Here's Why We Think Coloplast (CPH:COLO B) Is Well Worth Watching

Jul 12

Is There An Opportunity With Coloplast A/S' (CPH:COLO B) 45% Undervaluation?

May 23

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of kr.5.00

May 08

Coloplast (CPH:COLO B) Seems To Use Debt Rather Sparingly

Apr 13

Here's Why I Think Coloplast (CPH:COLO B) Is An Interesting Stock

Mar 29

Coloplast A/S (CPH:COLO B) Shares Could Be 41% Below Their Intrinsic Value Estimate

Feb 12

Coloplast (CPH:COLO B) Could Easily Take On More Debt

Jan 12

Is Now The Time To Put Coloplast (CPH:COLO B) On Your Watchlist?

Dec 28

Hissedar Getirileri

	COLO B	DK Medical Equipment	DK Pazar
7D	1.9%	1.9%	-0.9%
1Y	22.9%	22.8%	19.7%

Getiri vs. Endüstri: COLO B geçen yıl boyunca % 23.8 oranında getiri sağlayan Danish Medical Equipment sektörüyle eşleşti.

Getiri vs Piyasa: COLO B geçen yıl % 15 oranında getiri sağlayan Danish Piyasasını aştı.

Fiyat Oynaklığı

Is COLO B's price volatile compared to industry and market?
COLO B volatility
COLO B Average Weekly Movement	3.0%
Medical Equipment Industry Average Movement	5.6%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	8.9%
10% least volatile stocks in DK Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: COLO B son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: COLO B 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1954	16,019	Kristian Villumsen	www.coloplast.com

Coloplast A/S, Danimarka, Amerika Birleşik Devletleri, Birleşik Krallık, Fransa ve uluslararası alanda samimi sağlık ürünleri ve hizmetlerinin geliştirilmesi ve satışı ile ilgilenmektedir. Şirket, Kronik Bakım, Kontinans Bakımı, Ses ve Solunum Bakımı, Girişimsel Üroloji ve Gelişmiş Yara Bakımı segmentleri aracılığıyla faaliyet göstermektedir. Çeşitli ostomi türleri için bireysel vücut şekillerine uyum ve optimum takdir sağlayan SenSura Mio ve SenSura Ostomi bakım çözümlerinin yanı sıra Brava markası altında ostomi aksesuarları da dahil olmak üzere ostomi bakım ürünleri sunmaktadır.

Coloplast A/S Temel Bilgiler Özeti

Coloplast'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
COLO B temel i̇stati̇sti̇kler
Piyasa değeri	DKK 201.55b
Kazançlar(TTM)	DKK 4.97b
Gelir(TTM)	DKK 26.30b

40.6x

F/K Oranı

7.7x

P/S Oranı

COLO B aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
COLO B gelir tablosu (TTM)
Gelir	DKK 26.30b
Gelir Maliyeti	DKK 8.54b
Brüt Kâr	DKK 17.76b
Diğer Giderler	DKK 12.79b
Kazançlar	DKK 4.97b

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

Nov 05, 2024

Hisse başına kazanç (EPS)	22.09
Brüt Marj	67.52%
Net Kâr Marjı	18.88%
Borç/Özkaynak Oranı	142.3%

COLO B uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

2.3%

Mevcut Temettü Verimi

95%

Ödeme Oranı

COLO B Stoklara Genel Bakış

Ödüller

Risk Analizi

Coloplast A/S Rakipler

CPSE:DEMANT

DKK 58.6b

CPSE:AMBU B

DKK 34.5b

NasdaqGS:COO

US$21.3b

CPSE:EMBLA

DKK 14.4b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

President & CEO exercised options and sold kr.5.0m worth of stock

Executive Vice President of Growth exercised options to buy kr.28m worth of stock.

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Recent updates

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

President & CEO exercised options and sold kr.5.0m worth of stock

Executive Vice President of Growth exercised options to buy kr.28m worth of stock.

Coloplast A/S Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Are Investors Undervaluing Coloplast A/S (CPH:COLO B) By 38%?

Third quarter 2024 earnings: EPS misses analyst expectations

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Subdued Growth No Barrier To Coloplast A/S' (CPH:COLO B) Price

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Solid Earnings May Rest On Weak Foundations

Coloplast (CPH:COLO B) Is Due To Pay A Dividend Of DKK5.00

First half dividend of kr.5.00 announced

Analyst Estimates: Here's What Brokers Think Of Coloplast A/S (CPH:COLO B) After Its Interim Report

Coloplast A/S Revises Earnings Guidance for the Fiscal Year 2023/24

Second quarter 2024 earnings: EPS misses analyst expectations

A Look At The Fair Value Of Coloplast A/S (CPH:COLO B)

There's Reason For Concern Over Coloplast A/S' (CPH:COLO B) Price

Is Coloplast (CPH:COLO B) A Risky Investment?

President & CEO exercised options and sold kr.13m worth of stock

First quarter 2024 earnings: Revenues in line with analyst expectations

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Estimating The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S' (CPH:COLO B) Price Is Out Of Tune With Earnings

Coloplast A/S Approves the Distribution of Year-End Dividend

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast (CPH:COLO B) Strong Profits May Be Masking Some Underlying Issues

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Now 20% undervalued after recent price drop

A Look At The Intrinsic Value Of Coloplast A/S (CPH:COLO B)

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Deputy Chairman recently bought kr.40m worth of stock

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

New minor risk - Shareholder dilution

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Is Coloplast (CPH:COLO B) A Risky Investment?

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 18% Below Its Share Price

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast (CPH:COLO B) Seems To Use Debt Quite Sensibly

Coloplast A/S' (CPH:COLO B) Intrinsic Value Is Potentially 25% Below Its Share Price

First quarter 2023 earnings: EPS misses analyst expectations

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

These 4 Measures Indicate That Coloplast (CPH:COLO B) Is Using Debt Reasonably Well

Coloplast's (CPH:COLO B) Upcoming Dividend Will Be Larger Than Last Year's

Upcoming dividend of kr.15.00 per share

Here's Why We Think Coloplast A/S' (CPH:COLO B) CEO Compensation Looks Fair for the time being

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast's (CPH:COLO B) Shareholders Will Receive A Bigger Dividend Than Last Year

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

With EPS Growth And More, Coloplast (CPH:COLO B) Makes An Interesting Case

Coloplast Launches Saffron™ Fixation System for Prolapse Repair